跳至主要内容
临床试验/NL-OMON49774
NL-OMON49774已完成不适用

Conversion of collateral ventilation in CV-positive emphysema patients before endobronchial valve treatment - a pilot study (*MIND THE GAP CROSSING BORDERS*) - Mind the Gap Crossing Borders

niversitair Medisch Centrum Groningen0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Diagnosis of emphysema
  • 2. Subjects of both genders of at least 35 years of age at the time of the
  • baseline visit.
  • 3. Understand and voluntarily sign a patient informed consent form.
  • 4. 15 % predicted <= FEV1 <= 50% predicted.
  • 5. RV >= 175% predicted, and TLC >= 100% predicted and RV/TLC >= 55% predicted.
  • 6. 6MWD >= 140 meters.
  • 7. Dyspnea score of >=2 on the mMRC scale of 0-4.
  • 8. Non-smoker > 6 months prior to signing the informed consent.
  • 9. Chartis CV positive between target and ipsilateral lobe

排除标准

  • 1. Evidence of active pulmonary infection.
  • 2. Evidence of clinically significant bronchiectasis.
  • 3. History of more than 3 exacerbations with hospitalizations over the past 12
  • 4. Subject has DLCO <20% of predicted.
  • 5. Myocardial infarction or other relevant cardiovascular events in the past 6
  • 6. Prior lung surgery, Lung volume reduction surgery, lung transplantation,
  • lobectomy, or pneumonectomy.
  • 7. Prior endoscopic lung volume reduction.
  • 8. Unstable pulmonary nodule requiring follow-up
  • 9. Pregnant of nursing women.
  • 10. Hypercapnia defined by PaCO2 > 8.0kPa, or Hypoxemia defined by PaO2 <
  • 6.0kPa, both measured on room air.
  • 11. Any disease with high probability of mortality within 24 months.
  • 12. Patient is on an antiplatelet agent (such as Plavix) or anticoagulant
  • therapy (such as LMWH or coumarins).
  • 13. Patient was involved in other pulmonary drug studies within 30 days prior
  • to this study.

研究者

相似试验